2018年初，根据俄罗斯联邦政府大额竞争的结果创建的生物杂交技术实验室开始在圣彼得堡国立大学化学研究所工作。新单位由世界领先的药理学家之一Arto Urtti教授（芬兰）领导。

该项目的科学目标是创造一种基本的新生物材料——生物杂交材料，用于医学的许多治疗和诊断领域，通过结合活细胞和实验室合成分子以及超分子结构。生物杂交的开发是通过解决研究的各种层次问题来实现的:

合成新药，治疗肽，亲水聚合物和发光标记（分子水平）;
创建用于药物和遗传构建体（超分子水平）封装的生物相容性聚合物系统，
研究活细胞修饰方法（细胞水平）;
开发用于模拟聚合物药物递送系统和生物杂交（生命系统建模）的药代动力学的系统，使用模型动物（生物体）测试已开发的系统。

尽管所提出的系统与非常广泛的生物医学应用相关，但在本项目中，治疗系统的开发旨在治疗局部眼部疾病，如年龄相关性黄斑变性，青光眼和糖尿病相关性视网膜疾病。

At the beginning of 2018, the biohybridization Laboratory, created as a result of a large competition between the Russian Federal government, began work at the Institute of Chemistry of St. Petersburg State University. The new unit is headed by One of the world's leading pharmacologists, Professor Arto Urtti (Finland).

The scientific goal of the project is to create a fundamental new biomaterial - biohybrid material - for use in many therapeutic and diagnostic areas of medicine, synthesizing molecular and supramolecular structures by combining living cells with the laboratory. The development of biological hybridization is achieved by solving problems at various levels of research:

Synthesis of new drugs, therapeutic peptides, hydrophilic polymers and luminescent markers (molecular level);
Create biocompatible polymer systems for encapsulation of drug and genetic constructs (supramolecular level),
Study methods of modification of living cells (cell level);
Develop systems to simulate the pharmacokinetics of polymer drug delivery systems and biohybridization (life systems modeling), testing developed systems using model animals (organisms).

Although the proposed system is relevant to a very wide range of biomedical applications, in this project the therapeutic system was developed to treat topical ocular diseases such as age-related macular degeneration, glaucoma and diabetic retinal diseases.